Complications associated with the administration of iodine 131 in the treatment and follow-up of differentiated thyroid carcinoma

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 459-496-Thyroid Neoplasia & Case Reports
Clinical
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-488
Silvina Roxana Pozniak*1, Veronica Ilera2, Laura Elena Maffei3, Ana Rojkind4 and Maria Valeria Premrou5
1Consultorios Asociados de Endocrinologia, BSAS Capital Federal, Argentina, 2Hosp Ramos Mejia, Buenos Aires, Argentina, 3Consultorios Asociados De Endocr, Buenos Aires, Argentina, 4Consultorios asociados de Endocrinologia, Buenos Aires, Argentina, 5Consultorios Asociados de Endocrinologia, Tigre, Buenos Aires, Argentina
Title: Complications associated with the administration of iodine 131 in the treatment and follow-up of differentiated thyroid carcinoma

Authors: Pozniak,Silvina; Ilera, Veronica; Maffei,Laura Elena; Rojkind,Ana; Premrou, Maria Valeria

Consultorios Asociados de Endocrinología, Buenos Aires, Argentina

Introduction: Radioactive iodine (131-I) is used for the treatment and follow-up of differentiated thyroid cancer (DTC)in patients. 131-I is taken up by the salivary and lacrimal glands among others. Adverse events (AE) have been described in these organs secondary to the use of 131-I.

Objective: To analyze the frequency of AE in the oropharynx, salivary and lacrimal glands in patients with DTC who received I 131.

Material and methods: We retrospectively analyzed patients diagnosed with DTC and treated at a private endocrinology  center of Buenos Aires and surveyed by telephone about EA. We included patients with one or more follow-up scans after ablative dose and analyzed the correlation between the AE, the  131-I dose and clinical-pathological variables.

Results: We analyzed 129 patients , an average age of 45.43 years (19-86 years), 103 women (79.8%) and 26 men (20.2%).

127 patients (98.2%) had papillary thyroid carcinoma, follicular Ca-two patients (1.65%)

 EA  in 32 patients (24.8%). Among these patients AE observed : parotid pain in 2 patients, parotid swelling and enlargement in 15, submaxillary gland swelling 2 and parotid lithiasis 1. Also reported xerostomia 18,  dysgeusia 11,tooth decay 2 and xerophthalmia  in 7.

The correlation between the frequency of EAS with the following variables were analyzed:

- Pathology, all patients had papillary carcinoma type

- Cumulative dose received, patients with AE (EA+) had a mean dose of 194,83 mCi vs patient without EA (EA-) 156,2 p = NS (0.14)

- Ablative dose received, average dose  140.32 mCi for EA+ and 120 forAE-, p = S (0.03)

- Whole body scan dose, average dose  EA + 3,10 mCi vs EA- 2,80 mCi, p = NS (0.50)

- Age, EA + 40,69 years, and the EAS- 46,99, p = S (0.04)

- TNM, Low grade EAS + 31% and 20% in high grade, p = NS (0.33)

 Conclusions: The prevalence of AE in our population was 24.8%, similar to that described in the literature. Among those who had a higher incidence of EA after ablative dose were higher and younger patients, both variables showing statistically significant data. And we observed a greater tendency of EA with higher cumulative doses received and in patients with low-grade thyroid carcinomas. These results together with the new guidelines for DTC treatment and follow-up reinforce the need to carefully assess the use of I131 in patients with low grade thyroid carcinomas and young people to avoid AE.

Nothing to Disclose: SRP, VI, LEM, AR, MVP

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm